HeartMate II may be used to support patients either while they wait for a donor heart to become available or as a permanent, long-term therapy. For patients eligible for a heart transplant, usage of HeartMate II is known as "Bridge-to-Transplantation" (BTT). Utilization of the device with the intent of permanent, long-term support is known as "Destination Therapy" (DT). In either situation, without the option of an LVAD, AHF patients have poor prospects for survival and significantly limited lifestyles.,HeartMate II Facts:
- HeartMate II is the most widely used and extensively studied LVAD available today.
- More than 200 peer-reviewed publications have featured studies regarding the HeartMate II – far exceeding published data on all other LVADs combined.
- HeartMate II is the only available device FDA-approved for both Bridge-to-Transplantation (BTT) and Destination Therapy (DT), or long-term support.
- HeartMate II measures approximately three inches in length and weighs approximately 10 ounces. It has one moving part, a continuously spinning rotor that helps circulate blood.
- To date, HeartMate II has been implanted at over 290 medical centers across more than 35 countries in North America, Europe, the Middle East, Asia, Australia and Africa.
- The HeartMate II has demonstrated excellent and consistent outcomes in very sick patient populations. ,